Protective efficacy of intranasal vaccination with Mycobacterium bovis BCG against airway Mycobacterium tuberculosis challenge in mice

Journal of Infection

Volumn 53, Issue 5, 2006, Pages 350-356

  Giri, Pramod K ^a   Verma, Indu ^a   Khuller, G K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Bacillus Calmette Gu rin (BCG); Culture filtrate proteins (CFP); Intranasal (i.n.); Mycobacterium tuberculosis; Subcutaneous (s.c.)

Indexed keywords

BCG VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL IMMUNITY; BCG VACCINATION; CERVICAL LYMPH NODE; CONTROLLED STUDY; DRUG EFFICACY; LUNG BURDEN; LUNG TUBERCULOSIS; MEDIASTINUM LYMPH NODE; MOUSE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTECTION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BCG VACCINE; CYTOKINES; INJECTIONS, SUBCUTANEOUS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 33749511016     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2005.12.017     Document Type: Article

References (26)

1. Dye C., Scheele S., Dolin P., Pathania V., and Raviglione M.C. Consensus statement, global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO global surveillance and monitoring project. JAMA 282 (1999) 677
2. Fine P.E.M. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346 (1995) 1339-1345
3. Lagranderie M., Ravisse P., Marchal G., Gheorghiu M., Balasubramanian V., Weigeshaus E.H., et al. BCG-induced protection in guinea pigs vaccinated and challenged via the respiratory route. Tuber Lung Dis 74 (1993) 38-46
4. Lefford M.J. Induction and expression of immunity after BCG immunization. Infect Immun 18 (1977) 646-653
5. Lagranderie M.R., Balazuc A.M., Deriaud E., Leclerc C.D., and Gheorghiu M. Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infect Immun 64 (1996) 1-9
6. Lefford M.J. Immunization of mice after airborne infection with various strains of BCG. Am Rev Respir Dis 117 (1978) 103-109
7. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271 (1994) 698-702
8. Wang J., and Xing Z. Tuberculosis vaccines: the past, present and future. Expert Rev Vaccines 1 (2002) 341-354
9. Gallichan W.S., and Rosenthal K.L. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J Exp Med 184 (1996) 1879
10. McGhee J.R., Czerkinsky C., and Mestecky J. Mucosal vaccines: an overview. In: Ogra P.L., Lamm M.E., Bienenstock J., Mestecky J., Strober W., and McGhee J.R. (Eds). Mucosal immunology. 2nd ed. (1999), Academic, London 741-757
11. Davis S.S. Nasal vaccines. Adv Drug Deliv Rev 51 (2001) 21-42
12. Subrahmanyam D. Studies on the poly glycerophosphatides of Mycobacterium tuberculosis. Can J Biochem 42 (1964) 1192-1201
13. Andersen P., Askgaard D., Ljungqvist L., Bentzon M.W., and Heron I. T-cell proliferative response to antigens secreted by Mycobacterium tuberculosis. Infect Immun 59 (1991) 1558-1563
14. Rodriguez A., Blomberg M.T., Lindroth K., Ivanyi J., Singh M., and Fernandez C. B- and T-cell responses to the mycobacterium surface antigen PstS-1 in the respiratory tract and adjacent tissues role of adjuvants and routes of immunization. Vaccine 21 (2003) 458-467
15. Bowe F., Lavelle E.C., McNeela E.A., Hale C., Clare S., and Arico B. Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin. Infect Immun 72 (2004) 4052-4060
16. Abolhassani M., Lagranderie M., Chavarot P., Balazuc A.M., and Marchal G. Mycobacterial bovis BCG induces similar immune responses and protection by rectal and parenteral immunization routes. Infect Immun 68 (2000) 5657-5662
17. Lagranderie M., Chavarot P., Balazuc A.M., and Marchal G. Immunogenicity and protective capacity of Mycobacterium bovis BCG after oral and intragastric administration in mice. Vaccine 18 (2000) 1186-1195
18. Heritage P.L., Underdown B.J., Arsenault A.L., Snider D.P., and McDermott M.R. Comparison of murine nasal-associated lymphoid tissue and Peyer's patches. Am J Respir Crit Care Med 156 (1997) 1256-1262
19. Kyd J.M., Foxwell A.R., and Cripp A.W. Mucosal immunity in the lung and upper airway. Vaccine 19 (2001) 2527-2533
20. Chen L., Wang J., Zganiacz A., and Xing Z. Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Infect Immun 72 (2004) 238
21. Goonetilleke N.P., McShane H., Hannan C.M., Anderson R.J., Brooks R.H., and Hill A.V. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of Bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus ankara. J Immunol 171 (2003) 1602-1609
22. Lyadova I.V., Vordermeier H.M., Eruslanov E.B., Khaidukov S.V., Apt A.S., and Hewinson R.D. Intranasal BCG vaccination protects BALB/c mice against virulent Mycobacterium bovis and accelerates production of IFN-g in their lungs. Clin Exp Immunol 126 (2001) 274-279
23. Tree J.A., Williams A., Clark S., Hall G., Marsh P.D., and Ivanyi J. Intranasal bacille Calmette-Guérin (BCG) vaccine dosage needs balancing between protection and lung pathology. Clin Exp Immunol 138 (2004) 405-409
24. Campbell D.J., and Butcher E.C. Rapid acquisition of tissue-specific homing phenotypes by CD4+ T cells activated in cutaneous or mucosal lymphoid tissues. J Exp Med 195 (2002) 135
25. Brandtzaeg P., Farstad I.N., and Haraldsen G. Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Immunol Today 20 (1999) 267
26. Hoft D.F., Brown R.M., and Belshe R.B. Mucosal BCG vaccination of humans inhibits delayed-type hypersensitivity to purified protein derivative but induces mycobacteria-specific interferon-gamma responses. Clin Infect Dis 30 Suppl. 3 (2000) S217-S222